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Summary: Papillary renal cell carcinoma (pRCC) accounts for about 10% of renal parenchymal 
tumors. There are two pRCC subtypes reported in several studies, but so far  limited molecular 
evidence to validate this pRCC subtyping in daily routine. 
In this review we summarize relevant knowledge on pRCC regarding clinical, treatment options, 
and tumor features: clinical presentation, histopathology, electron microscopy, 
immunohistochemistry, cytogenetics, and genetic/ molecular. Genetic and molecular features have 
been used to track new tumor markers which may eventually enable the identification of new 
therapeutic targets. We present an overview of currently available pRCC treatment options and 
some of the new promising agents. Specific prognosis features of pRCC remain controversial.  
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1. Epidemiology 
Kidney cancer is the 13th most common malignancy worldwide, with ~ 271 000 new cases 
diagnosed in 2008 and ~ 116 000 people die from the disease [1]. Renal cell carcinoma (RCC) 
comprises about 3% of all solid tumors [2]. In Europe ~ 88 400 new cases of kidney cancer 
occurred in 2008, the 10th most common cancer [1]. RCC is extremely rare in the pediatric 
population and accounts for ~ 6% of malignant pediatric tumors (‹ 4% of pediatric renal tumors) 
[3]. 
The incidence of kidney cancer varies geographically: highest in Europe, North America, 
and Australia and lowest in India, Japan, Africa, and China [1]. The Czech Republic, Lithuania, 
Latvia, Estonia, and Iceland have the highest RCC rates in Europe, while incidence is lowest in 
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Romania, Cyprus, and Portugal [4]. In 2008, decreased or stabilized incidence in northern Europe 
countries occurred, particularly in Sweden, and generally increased (except for women in the early 
2000s) in Eastern Europe [5]. 
The mortality rates from kidney cancer in European Union (EU) peaked at 4.8/100 000 in 
1990–1994, and declined to 4.1 (−13%) in 2000–2004 [5].  In women in the EU, the corresponding 
values were 2.1 and 1.8 [5].  In Portugal mortality rates in women  declined (−14%) during 1990–
2004 [5]. 
Papillary RCC (pRCC) comprises ~ 6-18% of kidney tumors in reported series [6]. It is the 
most common histologic subtype observed in pediatric RCC and it was reported in 18 % of dialysis 
patients with less than 10 years of treatment [3, 7]. Atypical cysts with extensive papillary 
hyperplasia are often the precursors of papillary renal adenoma and cancer in these patients [8]. In 
children it may arise in the setting of pre-existing neoplasm, including Wilms tumor, metanephric 
adenoma, and metanephric adenofibroma [9]. Approximately 20% of pRCC are discovered as 
incidental findings [6]. 
Vikram et al. reported that the range of age is in the third to eighth decades, and male-to-
female ratio from 2:1 to 3.9:1 [2]. There are no reports on specific symptoms and signs of pRCC.  
 
2. Lifestyle Risk Factors  
Table 1 summarizes lifestyle risk factors and pRCC. 
Associated Risk Factors  Non-associated Risk Factors  Controversial Risk Factors  
Cigarette smoking 
 ACDK  
Obesity  Hypertension 
Animal products intake 
 Fat intake  
Table 1 – Life Risk factors and papillary RCC.  Acquired Cystic Disease- associated RCC (ACDK).[1, 7, 10-
14]  
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3. Genetic syndromes  
Table 2 summarizes genetic syndromes associated to pRCC. 
Syndrome Gene/location Gene product Papillary RCC Other tumors/lesions  
HPRCC  MET, 7q31.3; frequently exons 17, 
18 and 19; occasionally exon 16  
MET  Type 1: multiple, 
bilateral and 
multifocal  
Breast, pancreas, lung, skin, 
and stomach tumors 
HLRCC FH, 1q42-44  FH  Type 2: unilateral, 
solitary, aggressive; 
metastasis (~20% 
HLRCC families)  
Uterine and cutaneous 
leiomyoma/leiomyosarcoma 
PTEN-HTS  PTEN, 10q23  PTEN  Unifocal  Cerebellar dysplastic 
gangliocytoma, breast, thyroid 
(nonmedullary) and  
endometrial tumors, 
hamartomatous intestinal 
polyps, lipomas, fibromas  
BHD FLCN (BHD), 17p11  Folliculin  Multiple and bilateral  Fibrofolliculoma, 
trichodiscoma, acrochordon, 
colon and  kidney  tumors 
HPTJT CDC73 (HRPT2), 1q21-31  Parafibromin Bilateral  Renal hamartoma, 
nephroblastoma, uterine tumor, 
parathyroid tumor, fibro-
osseous mandibular and 
maxillary tumor  
FPTC Unknown gene, 1q21 Unknown  Multifocal  Renal adenoma and 
oncocytoma, papillary thyroid 
cancer, nodular thyroid disease  
Table 2 – Inhered papillary RCC. Hereditary papillary RCC (HPRCC); Hereditary leiomyomatosis RCC (HLRCC); 
Phosphatase and tensin homolog (PTEN); PTEN hamartoma tumor syndrome (PTEN-HTS); Birt-Hogg-Dubé syndrome 
(BHD); Folliculin gene (FLCN); Hyperparathyroidism-jaw tumor syndrome (HPTJT); Familial papillary thyroid cancer 
(FPTC); Met proto-oncogene (MET); Fumarate hydratase (FH); Cell division cycle 73 (CDC73); Hyperparathyroidism 2 
(with jaw tumor) HRPT2. [15-28] 
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In 1994 hereditary papillary renal cancer (HPRC) was reported as a rare autosomal 
dominant inherited syndrome with very high penetrance (30 families described so far), meaning 
that there is a high probability of a person developing pRCC by age 80 [16-18, 20, 29]. An early 
onset-form has been recently reported in which the disease appears in the second and third decade 
[29]. Diagnosis of this condition is based on the detection of germline mutation of the c-MET gene; 
c-MET mutations were reported to play a role in 13% of patients with pRCC and no family history 
of renal tumors [15, 16, 19, 30] (Table 1). Mutations of c-MET were also reported in a subset of 
tumors from patients with sporadic type 1 pRCC [31].  
             Hereditary leiomyomatosis RCC (HLRCC) mean age is 36–39 years, although the 
youngest age at diagnosis of pRCC in a fumarate  hydratase (FH) gene mutation carrier was 
reported in a 11-year-old patient [23, 24]. Among 89 cases reported in the literature, six (7%) were 
found in individuals younger than 20 years [25]. Two distinct FH mutations occurring in 
heterozygote (2bpdel, codon 181 and R300X) were reported in HLRCC families affected by renal 
cancer and uterine leiomyosarcoma [21]. The renal tumors associated to HLRCC tend to be 
hypovascular, solitary, and may metastasize early [17].  
Biallelic inactivation of succinate dehydrogenase gene (SDH) was reported as a pathway in 
the pathogenesis of pRCC [32]. Malinoc et al. based on the study of a small series, estimate that 
10% of individuals with SDHC gene mutation develop RCC (both clear and papillary type) [32]. 
4. Pathological features 
4.1 Macroscopic, Microscopic and Ultrastructural features 
Macroscopy [2, 33, 34] 
. Well-circumscribed, frequently with thick fibrous capsule or pseudocapsule 
. Mean size (range): 6.7-7.2 cm (1.2-26 cm) 
. Small tumors are usually solid, and large tumors show frequent cystic change 
. Yellow or brown cut surface 
. Frequent hemorrhage (8% of the cases) and necrosis 
. Bilaterality (4%) or multifocality (22.5%) can occur. 
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Microscopy [2, 35, 36]  
. Type 1 pRCC: small cuboidal or columnar cells with scant pale cytoplasm and hyperchromatic 
nuclei arranged on a single layer on basement membrane of papillary core;  psammoma bodies, 
foamy macrophages, glomeruloid papillae; lower nuclear grade than type 2; 
. Type 2 pRCC:  large cells with abundant eosinophilic granular cytoplasm and grade 3 nuclei 
(prominent nuclei); pseudostratified nuclei; variable foam cells and necrosis. 
 
Figure 1- Microscopic features of papillary RCC subtypes: A - Type 1 pRCC; B - Type 2 
pRCC. 
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Ultrastructure [35] 
. Type 1 pRCC: many glycogen granules, many secondary lysosomes containing lipid vacuoles, 
and few rough endoplasmic reticulum. 
. Type 2 pRCC: many mitochondria, few lipid vacuoles, and many smooth endoplasmic reticulum. 
 
In 1997, two consensus conferences, in Heidelberg, Germany, and Rochester, Minnesota, 
recognized the existence of benign papillary neoplasms of the renal tubular epithelium that are 
incidental findings, are much more common than clinically recognized pRCC [35]. At the 
Rochester conference it was recognized that there are no reliable histological differences between 
these small tumors and many clinically detected pRCC, and renal papillary adenoma was defined 
on the basis of size, less than 5mm, whereas larger tumors were classified as pRCC [35].  
Classically, tumors have been classified as pRCC if papillary structures comprise at least 
50% but a variety of other architectural patterns such as tubular, trabecular and solid were reported 
[15, 37]. Kovacs et al. suggested that more than 75% of the tumor being composed of papillary 
structures may be a better criteria for discriminating pRCCs from nonpapillary RCCs showing 3p 
deletions [37]. The presence of solid variants of pRCC that are composed of poorly formed papillae 
were reported and this group comprises at most <3% of all pRCC [15].  
The morphologic classification of pRCC into type 1 and 2 tumors has been supported by 
several histologic studies, although there is relatively limited molecular evidence to substantiate 
this subtyping [38]. Type 2 pRCC is composed of at least two genetically distinct subtypes: one 
subtype (type 2A) resembles type 1 in terms of indolent tumor behavior, excellent survival, low 
tumor grade, similar expression profiles, immunoreactivity, and inferred cytogenetic profiles; the 
other subtype (type 2B) is an highly metastatic, aggressive cancer that is molecularly distinct from 
type 1 or 2A tumors [38].  
 
4.2 Immunohistochemistry features 
Table 3 summarizes common immunohistochemical markers in pRCC. 
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Immunohistochemical markers of papillary RCC 
AE1/AE3 100%  
p 504 s 89.3 -100%                   Other types of RCCs are rarely positive. 
VIM 85.7-100 %  
CK7 90 % > 80% in type 1; 10-20% in type 2.  
PAX 2 85 -92.9 %  
CD10  67-93%  
PAX 8 87.5 %  
CLDN1 76-86%  
MUC1 89% Higher expression rates in type 1. 
MYC  67% (type 2 pRCC); 13% 
(other pRCC subtypes) 
High-grade type 2  
TOP2α 0.12-95.01% Higher expression rates in type 1 (0.12-
95.01% vs. 0.57–36.98%) than  in type 2, 
and high grade tumors.  
Table 3: Common immunohistochemical markers of papillary RCC. pRCC (papillary RCC); Cytokeratin 
AE1/AE3 (AE1/AE3); α-Methylacyl CoA racemase (P504S); Vimentin (VIM); Keratin 7 (CK7); Paired box 2 (PAX2); 
cluster differentiation marker 10 (CD10); Paired box 8 (PAX8); Claudin-1 (CLDN1); Carbonic anhydrase IX (CA9); 
Mucin 1 (MUC1); V-myc avian myelocytomatosis viral oncogene homolog (MYC); Topoisomerase (DNA) II alpha 
(TOP2α).  [15, 39-56]. 
 
Other immunohistochemical markers are expressed in pRCC but with less diagnosis impact 
than the immunohistochemical markers described on Table 3. 
Cell cycle fraction (Ki-67 index) and cell cycle rate (AgNOR score) are different when 
comparing the two histologic types of pRCC: both mean AgNOR score and mean Ki-67 index 
seem to be significantly higher in type 2 tumors [57].  
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4.3 Fine needle aspiration (FNA) [58] 
. Cells with moderate to scant cytoplasm 
. Small and uniform nuclei, often with prominent nuclear groves 
. Single and small nucleoli with mild to moderate hipercromasia and mild pleomorphism  
. Low to moderate nuclear/cytoplasm ratio 
. Foamy macrophages in the background 
. Intracellular hemosiderin 
. Psammoma bodies within the papillae, and in the background. 
 
Cytological features that are highly sensitive for the diagnosis of pRCC include 
intracytoplasmic hemosiderin and foamy macrophages [58]. These findings, in combination with 
the presence of papillae, nuclear grooves, inconspicuous nucleoli, increased nuclear to cytoplasmic 
ratio, are helpful in the FNA diagnosis of pRCC [58]. 
The presence of unusually numerous balls or three-dimensional clusters of cells with 
smooth borders represent the fragmented tips of the papillae [58]. This appearance may be an 
artifact, but is reproducible and may be useful for the diagnosis [58]. 
 
5.  Flow cytometry features 
DNA aneuploidy was reported in 50% pRCC [15]. According to del Vecchio et al. diploid 
and aneuploid patterns occur in 35% and 65% of tumors, respectively [59]; a strong correlation 
between nuclear grade and stage, as well as between nuclear grade/stage and ploidy pattern; and a 
strong correlation between nuclear grade/stage, ploidy pattern and clinical outcome. 
 
6. Chromosomal analysis 
Hierarchical clustering suggested two cytogenetic patterns that were reported to be 
common but not restricted to type 2 pRCC; one was characterized by combined high-level gains 
(ratios ≥2) of various chromosomes, including those commonly gained as primary and secondary 
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aberrations, and another by weakly correlated patterns of less common secondary chromosomal 
losses (ratios ≤1), including losses at 17p; there are increased numbers of chromosomal 
abnormalities in type 2 tumors [60] (Table 4). 
 
Chromosomal Abnormalities in papillary RCC 
Observation                         Description                             Comment 
Trisomy 7  80 % display copy number gain of the long arm of 
chromosome 7: 67% low-grade and 43% high-grade 
pRCC. Less number of cells with trisomy 7 in larger 
tumors.  
Trisomy 17 80% of pRCC The number of cells with trisomy 17 seems to 
increase with tumor growth; additional gains of 
chromosomes 12, 16, or 20 parallels malignant 
features.  
Trisomy 3 3q (43.1% pRCC) Occasionally associates with low-grade, and low-
stage. 
Gains 2 (20.7% pRCC) 
16q (32 -55%  pRCC),  
12q (28 - 41.4% pRCC),  
8q (19%  pRCC),  
3q (43.1% pRCC),  
20q (32 -50%  pRCC),  
loss of Y (87.2%  pRCC) 
5q (17.2% pRCC) 
13 q (17.2% pRCC) 
1 q (12.1% pRCC;  28% type 2 
pRCC) 
 Duplication of 8q may be a useful marker of worse 
prognosis. 
 
FBXO47 at 17q12 is often deleted. 
LOH  6q (40% pRCC), 9p (36% 
PRCC), 1p (24% PRCC), 4q 
(36% pRCC), 13q (36% 
pRCC), 11q (15.5% pRCC; in 
28% of type 2 pRCC), 3p (59% 
LOH at D9S171 (9q13) was associate with short 
survival. 
 
 
RASSF1A methylation in both type 1 and type 2. 
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pRCC) 
8p (12,1% PRCC; in 33% of 
type 2 pRCC)  
Y (73% pRCC), Xp (28% 
PRCC); Xq (36% PRCC) 
 
In pRCC, LOH at 3p25–26 was more common than 
at 3p14.2 and the first was not associated with 
mutations of the VHL gene.  
Table 4 - Chromosomal abnormalities in papillary RCC. F-box protein 47 (FBXO47); Loss of heterozygosity 
(LOH); Ras-association (RalGDS/AF-6) domain family member 1 (RASSF1A); Papillary renal cell carcinoma 
(translocation-associated) (PRCC); Transcription factor binding to IGHM enhancer 3 (TFE3); pRCC (papillary RCC); 
von Hippel-Lindau tumor supressor (VHL) [15, 37, 60-77]. 
 
Gains of chromosomes 12, 16, and 20 are present in small papillary adenomas and the 
frequencies of gains of chromosomes 7, 17, 16, 12, 20, and loss of the Y chromosome are similar in 
both adenomas and carcinomas [35] (Table 4).  
Papillary RCC with chromophilic cell type exhibit a set of chromosomal gains, 
characteristically including trisomies of chromosomes 7 and 17 [64]. Füzesi et al. reported three 
cases of pRCCs with clear cell cytomorphology showing loss of 3p but not trisomy of 17, and they 
concluded that pRCCs should be classified according to their cytomorphology rather than their 
growth pattern [15].  
Microsatellite analysis of chromosome 9p suggests the existence of a yet unknown tumor 
suppressor gene centromeric to the MTS locus on 9p21, which may play a role in pRCC 
progression [78].  
Gain of chromosomes 7p and 17p, loss of Y chromosome and additional gains 
(chromosome 3q, 8p, 12q, 16q and 20q) are frequently observed in type 1 pRCC, and chromosomal 
aberrations of type 2 pRCC show allelic imbalance of one or more of chromosomes 1p, 3p, 5, 6, 8, 
9p, 10, 11, 15, 18 and 22: losses of chromosome 11 and 18 mainly, losses of 8 and losses from the 
short arm of chromosome 9 exclusively were reported. [15, 39, 76, 77, 79]. In gene profile studies, 
high-grade type 2 tumors have been differentiated from a mixed group of pRCC consisting of type 
1 tumors, low-grade type 2 tumors, and tumors showing a mixed type 1 and low-grade type 2 
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morphology [38]. The considerable variation in the proportion of type 1 and 2 pRCC highlights the 
importance of assigning tumors into their correct subtype, according to established criteria [6]. 
Al-Saleem et al. reported a rare example of oncocytoma to pRCC progression with losses 
of chromosomes Y and 1, a common feature of oncocytoma, and a gain of chromosome 7, a feature 
of pRCC [80]. 
So far there are few reports of epigenetic alterations in pRCC. In one study of 61 tumors, 
TU3A (the candidate tumor suppressor gene – located at 3p21.1) was methylated in 42% of clear-
cell RCC and 25% of pRCC [81, 82]. The FHIT gene encompasses the common fragile site FRA3B 
at 3p14, involved in purine metabolism. FHIT promoter methylation is common (52 to 53%) in 
both clear-cell RCC and pRCC [81]. SPINT2 (serine peptidase inhibitor) which encodes a secreted 
inhibitor of c-MET activity (activating mutations in the c-MET proto-oncogene associate with 
familial pRCC, although somatic mutations are infrequent in sporadic pRCC) [81]. 
 
7. Treatment 
Table 5 summarizes pRCC treatment. 
Papillary RCC treatment 
. Surgery  
    Radical nephrectomy and lymph node dissection can cure early stage pRCC; relapses occur in 20–30% patients. 
. Systemic therapy 
     Renal tumors are highly resistant to both chemotherapy and radiotherapy.  
     Sunitinib (tyrosine kinase inhibitor), sorafenib (tyrosine kinase inhibitor) and temsirolimus (mTOR inhibitor) 
approved by US Food and Drug Administration. 
    Foretinib– tyrosine kinase inhibitor as well as of VEGR2 - ongoing Phase II clinical trial. 
Table 5 – Papillary RCC treatment.Mammalian target of rapamycin (mTOR); Vascular endothelial growth factor 
receptor 2 (VEGFR2); pRCC (papillary RCC)  [15, 29, 83-86]. 
 
Metastatic pRCC is characterized by resistance to systemic therapy and by poor survival 
[83]. The use of sunitinib and sorafenib, recently approved for advanced RCC, as well as other 
VEGF-based therapies warrant study in the clinical trials for patients with metastatic pRCC [83]. 
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Prospective efforts to characterize the activity of sunitinib in metastatic pRCC yielded 
disappointing response rates [84]. A recent study of 41 patients with metastatic pRCC receiving 
sunitinib (13 patients) or sorafenib treatment (28 patients) reported a low overall partial response 
rate of 4.8% (2 of 41 patients) [85]. Both responders were treated with sunitinib and had response 
durations of 8 and 12 months [85]. The Advanced Renal Cell Carcinoma Sorafenib Expanded 
Access Program allowed patients in the United States and Canada with metastatic RCC to receive 
treatment with sorafenib prior to its regulatory approval [86]. This non-randomized, open-label 
program treated 158 with pRCC out of 1891 patients [86]. Of the 107 evaluable subjects with 
pRCC, 90 (84%) had a measurable response to treatment with 3 partial responders and 87 with 
stable disease for at least 8 weeks, while 17 (16%) patients developed early progression on 
treatment [86]. 
Treatment specific to the c-MET mutation associated with pRCC remains to be identified 
[83]. 17AAG, which acts by inhibiting heat shock protein and affects c-MET activation, achieved 
responses in a Phase II trial limited to pRCC patients [83]. Preclinical data, studying a monoclonal 
antibody to the c-MET ligand, hepatocyte growth factor, reported antitumor activity, which could 
offer a future novel treatment for patients with c-MET-dependent tumors [83]. 
Hereditary papillary renal tumor tends to be occult and, if not detected and treated, can 
spread to other organs [29]. Parenchymal sparing surgery (partial nephrectomy) is recommended 
when the largest renal tumor approaches 3 cm in size [29]. Patients whose tumors are < 3 cm are 
generally managed with observation [29]. The goal of management is to maintain the patient’s 
renal function while minimizing the risk for metastasis [29]. 
Potential areas of systematic therapy for Hereditary Leiomyomatosis RCC will likely be 
designed to prevent increased HIF (Hypoxia induced factor) levels or target the transcription 
products of VHL-independent HIF accumulation, such as VEGF (Vascular endothelial growth 
factor) and TGF-α (Tumor growth factor alpha)/EGFR (Epidermal growth factor receptor) [16]. 
One attempt to block the downstream effectors of FH inactivation is through the use of erlotinib, an 
oral EGFR tyrosine kinase inhibitor (TKI) [16]. A multicenter phase II trial with this agent in 
patients with locally advanced and metastatic pRCC reported an overall RECIST (Response 
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evaluation criteria in solid tumors) response rate of 11% with an additional 24 patients (53%) 
experiencing stable disease [16]. Combination therapy with an mTOR inhibitor or VEGF pathway 
antagonist may potentiate the single agent activity of erlotinib [16]. A phase II trial of erlotinib 
(EGFR TKI) in combination with bevacizumab (monoclonal antibody against VEGF) is currently 
underway and is one of the trials designed to evaluate this strategy [16]. 
Rebecca Lim et al. reported a case of spontaneous regression of histologically confirmed 
metastatic type 2 pRCC in the absence of intervening systemic therapy or surgery [87]. 
 
8.  Prognosis 
Table 6 summarizes pRCC prognostic factors. 
Predictors  
TNM staging system  The predictive value of the 2010 TNM regarding CSS of pRCC is not superior when 
compared to the 2002 TNM.  
Nuclear grade Significant differences for CSS of pT1b vs. pT2a and pT3b vs. pT3c in pRCC. 
Histological subtype  Papillary histological subtype associates with good prognosis: low stage and grade, 
small tumor size and high % of CSS. 
 Type 2 is usually larger, advanced and less differentiated and displays more frequently 
necrosis and lymphovascular invasion compare to type 1. 
Type 2 pRCC can present extensive nodal metastasis. 
Tumor extension The inferior vena cava, the renal vein, or its branches (stage T3b and T3c) occurs in 
8.2%. Spread to mediastinal lymph nodes and supraclavicular lymph nodes are not 
unusual; such spread is considered to represent distant metastases and classified as M1 
disease. Nodal involvement is not necessarily associated with worst prognosis. 
Visceral metastases in 5.7%–11%, including lung, bone and brain, and low median 
survival (9.1 months). 
Tumor necrosis Controversial parameter as negative predictor for metastasis-free and overall survival. 
FN1 Increased FN1 mRNA expression seems to correlate to aggressive behavior. 
EGF-R Intermediate/strong EGF-R expression seems to associate to higher tumor grade, 
distant metastasis, and worst long-term survival. 
Claudin-1  Loss of claudin-1 expression occurs in aggressive tumors and associates to shortened 
disease-specific survival  
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IMP3  IMP3 expression may predict tumor metastasis in patients with localized disease. 
Chromosomal 
abnormalities 
Losses of 8p, 9p, and 11q associate with higher T-stage and higher clinical stage, loss 
of 8p with positive M-stage, and loss of 9p and gain of 3q with positive N-stage. 
Polysomy 7 associates with higher nuclear grade and higher pathological stage.  
Table 6 – Prognostic factors. Tumor-node-metastasis classification system (TNM); cancer-specific survival (CSS); 
Epidermal Growth Factor Receptor (EGF-R); Fibronectin (FN1); Insulin-like growth factor 2 mRNA binding protein 3 
(IMP3); pRCC (papillary renal cell carcinoma). [2, 15, 44, 60, 88-97] 
 
Two large pediatric series report the outcome of 32 patients with pRCC [9]. 75 % (24/32) 
presented with disease limited to the kidney, and 22 of the 24 were free of disease; death from 
disease occurred in one T2N0MX tumor and the other died from other causes [9]. Of the remaining 
eight patients with higher stage disease, three (T4N0MX, T3N1M0,T2,N2,M0) died of their 
disease [9].  
Future Perspectives 
Papillary RCC is the second most common renal cell carcinoma. Regrettably pRCC is 
usually asymptomatic or without specific symptoms and signs, and approximately 20% of pRCC 
are incidental findings. There are no specific tumor markers available for diagnostic, prognostic or 
predictive purposes. Papillary RCC diagnosis, prognosis and treatment are based on 
histopathologic features but their subtyping seems unsatisfactory. Molecular profiling is an 
emerging promising tool for new biomarker identification that may provide a better understanding 
of pRCC pathogenesis and eventually improve the accuracy of predicting prognosis and treatment 
of patients. 
 
Executive Summary 
Executive Summary 
Epidemiology 
Papillary RCC (pRCC) account for ~ 10% of renal cell tumors 
pRCC is the most common histologic subtype in pediatric RCC 
Range of age: third to eighth decades; male-to-female ratio: 2:1 to 3.9:1 
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Lifestyle Risk Factors 
Cigarette smoking and ACKD associate with pRCC, but not obesity; hypertension and fat or animal product intake 
remain controversial 
Genetic syndromes 
Inhered pRCC: Hereditary papillary RCC (HPRCC); Hereditary leiomyomatosis RCC (HLRCC); PTEN hamartoma 
tumor syndrome (PTEN-HTS); Birt-Hogg-Dubé syndrome (BHD); Hyperparathyroidism-jaw tumor syndrome (HPTJT); 
Familial papillary thyroid cancer (FPTC)  
Pathological features 
The morphologic classification of pRCC into type 1 and 2 tumors is supported by several studies but with limited 
molecular evidence to substantiate this subtyping  
Immunohistochemical markers  
p504s (89.3 – 100%), rarely in other RCC; CK7 (90%:  > 80% in type 1; 10-20% in type 2); MUC 1 and TOP2α with 
higher expression in type 1 pRCC; MYC in 67% of type 2 pRCC 
Chromosomal abnormalities  
Main pRCC chromosomal abnormalities: trisomy 7, 17 and 3; others gains (2, 16q, 12q, 8q, 3q, 20q, 5q, 13q, 1q), loss 
of Y, LOH (6q, 9p, 1p, 4q, 13q, 11q, 3p, 8p, Y, Xp, Xq) 
Gain of chromosomes 7p and 17p, loss of Y chromosome and additional gains (chromosome 3q, 8p, 12q, 16q and 20q) 
frequent in type 1 pRCC; chromosomal aberrations of type 2 pRCC show allelic imbalance of one or more 
chromosomes: 1p, 3p, 5, 6, 8, 9p, 10, 11, 15, 18 and 22 
Treatment 
Radical nephrectomy and lymph node dissection can cure early stage pRCC; relapses in 20–30% 
Highly resistant to both chemotherapy and radiotherapy; Sunitinib (tyrosine kinase inhibitor), sorafenib (tyrosine kinase 
inhibitor) and temsirolimus (mTOR inhibitor) approved by US Food and Drug Administration; Foretinib – tyrosine 
kinase inhibitor as well as of VEGR2 - ongoing Phase II clinical trial 
Prognosis 
Specific prognosis features of pRCC remain controversial 
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